Renal cell carcinoma

Current Opinion in Oncology

Volumn 14, Issue 3, 2002, Pages 280-285

  Godley, Paul ^a   Kim, Steven W ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BIOMED 101; CYTOTOXIC AGENT; DOCETAXEL; FAS ANTIBODY; FLUOROURACIL; GENE PRODUCT; GLYCOPROTEIN P; IM 862; INTERLEUKIN 2; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG;

CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RISK; CANCER SURGERY; CAPILLARY LEAK SYNDROME; CLINICAL TRIAL; DRUG MEGADOSE; GENETIC DISORDER; HUMAN; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; METASTASIS; MOLECULAR GENETICS; NEPHRECTOMY; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS;

EID: 0036250148     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200205000-00005     Document Type: Review

References (52)

1. Estimates of the worldwide incidence of 25 major cancers in 1990
2. Precancerous lesions in the kidney
3. Rising incidence of renal cell cancer in the United States
4. Incidental renal cell carcinoma-age and stage characterization and clinical implications: Study of 1092 patients (1987-1997)
5. Estimates of the worldwide mortality from 25 cancers in 1990
6. Increase of renal cell carcinoma incidence in central Europe
7. Clinically unrecognized renal cell carcinoma: Diagnostic and pathologic aspects
8. Occupational risk factors for renal cell carcinoma: Agent-specific results from a case-control study in Germany
9. Increasing incidence of renal cell cancer
10. Molecular genetics of renal cell carcinoma
11. Association of a novel constitutional translocation t(1q;3q) with familial renal cell carcinoma
12. VHL gene alterations in renal cell carcinoma patients: Novel hotspot or founder mutations and linkage disequilibrium
13. Long-term treatment with low doses of interleukin-2 and interferon-α: Immunologic effects in advanced renal cell cancer
14. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10 Year experience
15. Tuberous sclerosis gene products in proliferation control
16. Birt-Hogg-Dube syndrome: Mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2
17. Prognostic significance of the 1997 TNM classification of renal cell carcinoma
18. The impact of a 4 cm. cutoff point for stratification of T1N0M0 renal cell carcinoma after radical nephrectomy
19. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome
20. Impact of tumor size on the clinical outcomes of patients with Robson stage I renal cell carcinoma
21. A postoperative prognostic nomogram for renal cell carcinoma
22. Improved prognostication of renal cell carcinoma using an integrated staging system
23. Validation of the UCLA integrated staging system for patients with renal cell carcinoma
24. Tumor associated trypsin inhibitor as a prognostic factor in renal cell carcinoma
25. Metallothionein expression in renal cell carcinoma: Subcellular localization and prognostic significance
26. Thymidine phosphorylase/platelet-derived endothelial cell growth factor (PD-ECGF) associated with prognosis in renal cell carcinoma
27. Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence
28. Molecular markers for renal cell carcinoma: Impact on diagnosis and treatment
29. Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification
30. Nephron sparing surgery for renal tumors: Indications, techniques and outcomes
31. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney
32. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-Year followup
33. Adrenal sparing surgery during radical nephrectomy in patients with renal cell cancer: A new algorithm
34. Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies
35. Laprascopic surgery for stage T1 renal cell carcinoma: Radical nephrectomy and wedge resection
36. The long-term outcome of laparoscopic radical nephrectomy for small renal cell carcinoma
37. Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: A phase II study
38. A phase II trial of weekly intravenous gemcitabine and cisplatin with prolonged continuous infusion 5-fluorouracil in patients with metastatic renal cell carcinoma
39. Phase II trial of the anti-angiogenic agent IM 862 in metastatic renal cell carcinoma
40. A phase II trial of weekly intravenous gemcitabine with prolonged continuous infusion 5-fluorouracil and oral thalidomide in patients with metastatic renal cell cancer
41. Oxaliplatin, fluorouracil and folinic acid (FOLFOX) in patients with metastatic renal cell carcinoma
42. Phase II trial of single agent, weekly docetaxel in advanced or metastatic renal cell carcinoma
43. Increased intracellular doxorubicin by anti-Fas monoclonal antibody: A mechanism that enhances the cytotoxicity in renal cell carcinoma cells
44. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma
45. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma
46. A phase II study of interferon α and low-dose subcutaneous interleukin-2 in advanced renal cell carcinoma
47. Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma
48. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil
49. A randomized phase III trial of high-dose interleukin-2 versus subcutaneous IL-2/interferon in patients with metastatic renal cell carcinoma
50. Phase I dose escalation study with the leukotriene B4 receptor antagonist biomed 101 in renal cell cancer patients receiving high-dose IL-2
51. Interferon adjuvant to radical nephrectomy in Robson stages II and II renal cell carcinoma: A multicentric randomized study
52. Adjuvant therapy of renal cell carcinoma patients with a pure cell-lysate autologous tumor vaccine: A 5-year follow-up analysis